pacman schreef op 13 januari 2021 10:40:
Summary
Pharming Group N.V. has filed to offer an estimated $10.9 million in Registered Holder shares in a U.S. offering.
The firm is commercializing a treatment for hereditary angioedema and developing a treatment for pneumonia brought on by the Covid-19 virus.
The firm is generating revenue growth, profits and free cash flow, so the offering is worth considering.
Quick Take
Pharming Group N.V. (PHAR) has filed to raise $10.9 million in an offering by Registered Holders of its ADSs representing underlying ordinary shares, according to an F-1 registration statement.
The company is developing and commercializing treatments for acute hereditary angioedema and other disease conditions.
PHAR is well into the commercialization phase for its lead drug, has several notable collaborations with major pharma research groups and is generating profits and increasing cash flow from operations.
For life science investors, the offering is worth close consideration.